Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Abstract

Abstract-The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued anevidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) Ͻ100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is Ͻ100 mg/dL, but when risk is very high, an LDL-C goal of Ͻ70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C Ͻ100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2ϩ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is Ͻ130 mg/dL, but an LDL-C goal Ͻ100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.

Relationship between preclinical abnormalities of global and regional left ventricular function and insulin resistance in severe obesity: a Color Doppler Imaging Study

“…All obese patients had normal plasma levels of total cholesterol (o200 mg/dl), of low-density lipoprotein cholesterol (LDL-C) (o130 mg/ dl), normal high-density lipoprotein cholesterol (HDL-C) (445 mg/dl) and normal triglycerides level (o150 mg/dl). 14 All obese subjects showed normal values of thyroid function. No obese patients were taking drugs.…”

Potential impact of renin–angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients

“…Dyslipidemia was defined as: total cholesterol^220 mg dl À1 ; high-density lipoprotein (HDL) cholesterol o40 mg dl À1 for men, o50 mg dl À1 for women or triglyceride^150 mg dl À1 ; or current use of an antihyperlipidemic medication. Metabolic syndrome (MS) criteria were determined using a modified version of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Pressure (Adult Treatment Panel III) 10 as follows: (1) medication for hypertension or systolic blood pressure (BP) X130 and/or diastolic pressure X85 mm Hg; (2) triglycerides X150 mg dl À1 ; (3) HDL cholesterol o40 mg dl À1 for men and o50 mg dl À1 for women; (4) medication for diabetes or HbA 1c X6.0%; and (5) WC 485 cm for men and X90 cm for women, which is the definition of MS in Japan. 11 Because data on fasting glucose was only available in a subsample of fasting subjects, we assessed HbA 1c instead.…”

The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention

“…There continues to be a window of opportunity to further optimize use of this proven, effective therapy in a high-risk PCI cohort. Furthermore, monitoring of cholesterol levels, aggressive titration of lipid-lowering therapy to achieve target levels and attention to medication adherence by patients is necessary for patients already receiving lipidlowering therapy (32).…”